Currently, there are 602.80M common shares owned by the public and among those 552.62M shares have been available to trade.
The company’s stock has a 5-day price change of 6.07% and 4.61% over the past three months. GERN shares are trading 115.17% year to date (YTD), with the 12-month market performance up to 109.22% higher. It has a 12-month low price of $1.64 and touched a high of $5.34 over the same period. GERN has an average intraday trading volume of 9.21 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 1.62%, 0.19%, and 30.30% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Geron Corp. (NASDAQ: GERN) shares accounts for 69.62% of the company’s 602.80M shares outstanding.
It has a market capitalization of $2.74B and a beta (3y monthly) value of 0.50. The earnings-per-share (ttm) stands at -$0.36. Price movements for the stock have been influenced by the stock’s volatility, which stands at 4.94% over the week and 5.12% over the month.
Earnings per share for the fiscal year are expected to decrease by -7.93%, and 66.67% over the next financial year. EPS should grow at an annualized rate of 5.00% over the next five years, compared to -16.08% over the past 5-year period.
Looking at the support for the GERN, a number of firms have released research notes about the stock. Leerink Partners stated their Outperform rating for the stock in a research note on September 09, 2024, with the firm’s price target at $7. Robert W. Baird coverage for the Geron Corp. (GERN) stock in a research note released on April 30, 2024 offered a Neutral rating with a price target of $4.50. TD Cowen was of a view on April 29, 2024 that the stock is Buy, while Needham gave the stock Buy rating on March 15, 2024, issuing a price target of $4- $5. Goldman on their part issued Buy rating on September 12, 2023.
